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Abstract
Background: Terminal differentiation of NK cells is crucial in maintaining broad responsiveness to pathogens and
discriminating normal cells from cells in distress. Although it is well established that KIRs, in conjunction with NKG2A, play a
major role in the NK cell education that determines whether cells will end up competent or hyporesponsive, the events
underlying the differentiation are still debated.
Methodology/Principal Findings: A combination of complementary approaches to assess the kinetics of the appearance of
each subset during development allowed us to obtain new insights into these terminal stages of differentiation,
characterising their gene expression profiles at a pan-genomic level, their distinct surface receptor patterns and their
prototypic effector functions. The present study supports the hypothesis that CD56
dim cells derive from the CD56
bright
subset and suggests that NK cell responsiveness is determined by persistent inhibitory signals received during their
education. We report here the inverse correlation of NKG2A expression with KIR expression and explore whether this
correlation bestows functional competence on NK cells. We show that CD56
dimNKG2A
2KIR
+ cells display the most
differentiated phenotype associated to their unique ability to respond against HLA-E+ target cells. Importantly, after IL-12 +
IL-18 stimulation, reacquisition of NKG2A strongly correlates with IFN-c production in CD56
dimNKG2A
2 NK cells.
Conclusions/Significance: Together, these findings call for the reclassification of mature human NK cells into distinct
subsets and support a new model, in which the NK cell differentiation and functional fate are based on a stepwise decrease
of NKG2A and acquisition of KIRs.
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Introduction
NK cells are one component of the innate immune system, able
to recognise various targets without specific sensitisation. They
constitute a first line of defence and can kill infected and tumour
cells. Mature NK cells are heterogeneous and differ in their
proliferative potential, homing characteristics, functional capaci-
ties and responses to a wide range of cytokines [1,2]. The
complexity of the NK cell compartment is attributable to the vast
network of receptors that are expressed on NK cell surfaces, which
allow them to recognise target cells. These receptors can be either
inhibitory or activating, and it is the balance between these
opposing signals that dictates the functional status of the cells [3].
Around 10% of the NK cells in peripheral blood are CD56
bright;
this immunoregulatory subset produces a wide range of cytokines
and chemokines after monokine stimulation, but its ability to kill
target cells spontaneously is poor. In contrast, the remaining 90%
of the NK cells, the CD56
dim cytotoxic NK cell subset, produces
relatively lower cytokine levels, but possesses an abundance of
cytolytic granules and can spontaneously lyse susceptible target
cells [4].
The precise relationship between these two major NK cell
subsets, CD56
bright and CD56
dim, has long been debated. Several
recent reports have finally shown quite convincingly that
CD56
bright NK cells are very likely precursors of the CD56
dim
subset: the shorter telomeres of the latter, in both peripheral blood
and lymph nodes, imply that they are older than the former [5,6].
In addition, Romagnani et al have shown in vivo that efferent lymph
nodes contain a substantial proportion of CD56
dim KIR
+ NK cells
[6]. Very recently, Yu et al reinforced the concept of a transi-
tion from CD56
bright to CD56
dim cells, proposing CD94 as a
developmental intermediary between these NK cell subsets [7].
Along with others, we have demonstrated that NK cells are the
first lymphocytes appearing in patients recovering from hemato-
poietic stem cell transplantation (HSCT) and that these cells are
constituted mainly from CD56
bright NK cells [8,9,10,11].
Other and we have shown that CD56
dim NK cells from patients
who have recently had hematopoietic transplantations transiently
overexpress NKG2A, compared with cells from healthy donors
[8,10,11]. In addition, CD56
dim NK cells from cord blood highly
over-expressed NKG2A [12]. Altogether, these data suggest that
the modulation of NKG2A expression among CD56
dim cells may
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inhibitory NK receptor that has been reported to form disulfide-
linked heterodimers with invariant CD94. The NKG2A ligand has
been identified as HLA-E, a non-classical MHC class-Ib molecule
that is widely distributed among various tissues, exhibits relatively
low surface expression, and has limited polymorphism [13]. The
cross-linking of NKG2A by target cells bearing HLA-E results in
NK cells inhibition through the phosphorylation of the two
immunoreceptor Tyr-based inhibitory motifs (ITIMs) present in
the intracellular tail of NKG2A [14].
Although it is well established that KIRs, in conjunction with
NKG2A, play a major role in the NK cell education that
determines whether cells will end up competent or hyporespon-
sive, the mechanisms underlying this education are still debated
[15]. One hypothesis proposes that the engagement of self-MHC-
specific inhibitory receptors directly renders NK cells functional,
‘‘licensing’’ them, so to speak. The ‘‘disarming’’ model, on the
other hand, suggests that the hyporesponsiveness of NK cells
lacking self-MHC-specific inhibitory receptors is a consequence of
the persistent stimulation of previously competent cells. More
recently a new ‘‘rheostat’’ model argues that the responsiveness of
each NK cell is tuned by the input of inhibitory receptors
[16,17,18].
Here we used a combination of complementary approaches that
assess the kinetics of the appearance of each subset during
development to examine the terminal stages of differentiation in
the light of these hypotheses and to develop a detailed model that
integrates our new insights with recent findings by others. All the
observations from this study support the previous hypothesis that
CD56
dim cells derive from the CD56
bright NK cell subset.
Furthermore, this study provides the first phenotypic and
functional analysis of mature CD56
dim subsets that focuses on
the progressive decrease in NKG2A expression and the sequential
acquisition of KIRs. We thus put forward a new model of terminal
differentiation that starts at the CD56
bright stage and leads through
the following stages: CD56
dimNKG2A
+KIR
2CD56
dimNKG2A
+
KIR
+ CD56
dimNKG2A
2KIR
+. Our data support the concept
that terminally differentiated CD56
dimNKG2A
2KIR
+ NK cells
are fully competents, able to kill HLA-E
+ targets, or alternatively
CD56
dimNKG2A
2KIR
2 hyporesponsive NK cells, due to im-
paired KIR acquisition.
Materials and Methods
Samples collection and treatment
All samples used in this study derived from anonymous
individuals at the EFS (Etablissement Franc ¸ais du Sang), the
National Blood Service. Written Informed consent was obtained
for each donor. This study was approved by the institutional
review board at Pitie ´-Salpe ˆtrie `re Hospital (Paris, France). PBMC
were isolated using Ficoll gradient immediately following collec-
tion. Cells were thereafter used for different tests.
Flow cytometry
Five-colour fluorescent activated cell-sorting analysis was
performed on freshly harvested PBMCs, or whole blood cells for
post-UCBT. Cells were stained with the appropriate antibody
cocktail: anti-CD3 (UCHT1; Beckman Coulter), anti-CD56
(N901; Beckman Coulter), anti-CD16 (3G8; Beckman Coulter or
VEP13; Miltenyi biotec), anti-CD94 (HP-3D9; Becton Dickinson),
anti-CD159a/NKG2A (Z199; Beckman Coulter), anti-NKG2C
(134591; R&D systems), anti-CD85j/ILT2 (HP-F1; Beckman
Coulter), anti-CD27 (B1.49.9; Beckman Coulter), anti-CD62L
(MEL-14; Becton Dickinson), anti-CD57 (S-HCL-1; Becton
Dickinson), anti-Siglec-9 (191240; R&D Systems) and anti-FCRL6
(2H3; BioLegend). Global KIR analysis was performed with an
anti-KIR antibody mix: anti-KIR2DL1/KIR2DS1 (EB6B; Beck-
man Coulter), anti-KIR2DL2/KIR2DL3/KIR2DS2 (GL183;
Beckman Coulter) and anti-KIR3DL1/KIR3DS1 (Z27; Beckman
Coulter). Single KIR analysis was performed by subtraction to
discriminate between KIR2DS1 and KIR2DL1, in the presence of
anti-KIR2DL1 (143211; R&D Systems) and anti-KIR2DL1/
KIR2DS1. Similarly, KIR2DL2 and KIR2DL3 were discrimi-
nated with anti-KIR2DL3, (180701; R&D Systems) and anti-
KIR2DL2/DL3 (DX27, Miltenyi Biotec). Other single KIRs were
detected with anti-KIR3DL1 (DX9; R&D Systems), anti-
KIR2DS4 (179315; R&D Systems) or anti-KIR2DL5 (UP-R1;
E-Biosciences). FACS lysing solution (Becton Dickinson) was used
to lyse erythrocytes for whole blood staining. Cells were
permeabilised for intracellular staining with cytofix/cytoperm kit
(Becton Dickinson) and then stained with anti-granzyme-K
(GM6C3; Santa Cruz) or anti-IFN-c (B27, BD Biosciences) mAbs.
IFN-c staining was performed after overnight incubation in the
presence of 10 ng/ml IL-12 (R&D Systems) plus 100 ng/ml IL-18
(R&D Systems).
Microarray analysis
10
4 cells of CD56
brightCD16
2, CD56
dimNKG2A
+ and
CD56
dimNKG2A
2 NK cell subsets from four different healthy
donors were sorted by FACS. Purified cells were collected and
then resuspended in SuperAmp
TM Lysis Buffer (Miltenyi Biotec,
Cologne, Germany). The Agilent 2100 Bioanalyzer System
(Miltenyi Biotec) was used to control total RNA quality. Gene
expression analysis was performed with the Human Whole
Genome Oligo Microarray (44 K), as a commercial service by
Miltenyi Biotec, to reveal a gene expression profile for each NK
cell subset of every individual donor. The Agilent Feature
Extraction Software was used to read out and process the
microarray image. Data were then normalised by dividing each
reporter signal with the median signal intensity of the whole
microarray, and then filtered to remove noisily or arbitrarily
regulated genes with expression levels close to background.
Reporters with expression intensities of less than 10% of the array
median were removed from the dataset. Thus 33,867 of the 41,000
genes with strong reliable signals were sorted and then analysed
with TM4 software [19]. Complete linkage hierarchical cluster-
ing was then performed on the significantly modulated genes
(p,0.01), with one-way ANOVA. Each cluster was then individ-
ually used for ontogenetic analysis using Panther-BP (in the gene
ontology section) of DAVID software [20,21]. All microarray data
are MIAME compliant and raw data have been deposited in the
MIAME compliant database ArrayExpress (accession number:
E-MEXP-2798).
Cell sorting
Whole NK cells from freshly isolated PBMCs were negatively
purified with a MACS NK cell isolation Kit (Miltenyi biotec). The
various subsets of NK cells were sorted with a BD FACS-Aria
(Becton Dickinson) cell sorter from purified NK cells in the
presence of anti-CD3 (UCHT1; Beckman Coulter), anti-CD56
(N901; Beckman Coulter), anti-NKG2A (Z199; Beckman Coul-
ter), and anti-CD16 (VEP13, Miltenyi). Post-sorting purities were
routinely .96%. NK subsets were then used for the microarrays
and for IFN-c production assays.
Degranulation assays
Degranulation assays used CD107a detection, as previously
described [11]. PBMC were resuspended at a 1:1 ratio in the
Terminal NK Differentiation
PLoS ONE | www.plosone.org 2 August 2010 | Volume 5 | Issue 8 | e11966presence of target cells and anti-CD107a mAb (H4A3; Becton
Dickinson). After 1 h incubation, monensin was added at 2 mM
for an additional 4 h of incubation. Degranulation was assayed
against MHC class-I-deficient K562, 721.221 target cells, and
LCL-221-AEA, which expresses the HLA-E*0101 allele [22].
Antibody-dependant cell cytotoxicity assays were performed
against CD20
+ RAJI cells in the presence of 1 mg/ml of anti-
CD20 (rituximab, Roche).
Statistical analysis
Mann Whitney tests were performed for individual comparisons
of two independent groups. Wilcoxon tests were performed for
individual comparison of the paired groups. Repeated measures
ANOVA with Tukey post-test for P-value calculation were
performed for multiple comparisons assays. Statistical analysis
used Prism 5 software (GraphPad Software, San Diego, CA). P
value less than 0.05 were considered as significant. 1*=p,0.05;
2*=p,0.01; 3*=p,0.001.
Results
Phenotypic and transcriptomic profile of CD56
bright,
CD56
dimNKG2A
+ and CD56
dimNKG2A
2 subsets
In order to better characterize the last steps of NK cell
differentiation, we analysed the expression patterns of NK
receptors and other maturation molecules on CD56
bright,
CD56
dimNKG2A
+, and CD56
dimNKG2A
2 cells from healthy
controls by flow cytometry. As shown in Fig. 1, CD62L,
granzyme-K and CD27 were highly expressed in CD56
bright NK
cells, but more importantly their expression progressively de-
creased in CD56
dimNKG2A
+ and CD56
dimNKG2A
2 NK cells.
Inversely, CD57, ILT2, FCRL6 and Siglec-9 progressively
accumulated when looking sequentially these subsets. In contrast,
other NK markers distinguished only CD56
bright and CD56
dim.
These included Pen5, CD8a, perforin and granzyme-B, which
were expressed mainly on CD56
dim cells, independently of
NKG2A expression. NKp44, CCR7, CD127 and CD117 were
expressed almost exclusively on CD56
bright NK cells (data not
shown). Finally, these three NK cell subsets were indistinguishable
for the other receptors tested, including NKp30, NKp46,
NKG2D, 2B4, LAIR-1, DNAM, CD11a and CD11b (data not
shown). Of note, NKG2A is covalently associated with CD94 to
form heterodimers and, as expected, expression of NKG2A and of
CD94 was highly correlated (Figure S1). However, CD94
expression is also linked to that of NKG2C, an activating NK
receptor that, like NKG2A, recognises HLA-E [23]. NKG2C is
poorly expressed on NK cells from healthy donors. The CD56
dim
NK subset expressed NKG2C and NKG2A mainly separately
while the CD56
brightNKG2C
+ subset co-expressed NKG2A
(Figure S1) [24].
In an attempt to better characterize the different NK cell
subsets, we compared the gene expression profiles of CD56
bright,
CD56
dimNKG2A
+, and CD56
dimNKG2A
2 NK cells. The
analysis of variance revealed that 723 of the 41,000 genes tested
showed significant changes in gene expression between the subsets
at a p value (significance level) of p,0.01 (Table S1). The
hierarchical clustering analysis of the differentially expressed genes
revealed only six clusters (Fig. 2A). As expected, among the genes
downregulated in cluster 1 (30 genes) and overexpressed in cluster
5 (125 genes) during the transition between CD56
bright to
CD56
dim, regardless of NKG2A expression, were some KIRs
(Kir3DL1, Kir2DS4 and Kir2DL5A), other NK cell-surface
receptors: (CD6, CD16a, 2B4, CD48 and CD62L), chemokines
(CCL3, CCL4, CCL5, CCL3L3 and CCL23), and signalling
molecules (STAT2, STAT4 and LAT2) (Table S2).
More interestingly, this gene profiling analysis largely confirmed
that the CD56
dimNKG2A
+ subset mainly display an intermediary
profile between CD56
bright and CD56
dimNKG2A
2 subsets.
Indeed, the largest clusters, cluster 2 (212 genes) and cluster 4
(155 genes), corresponded to genes that were downregulated or
overexpressed, respectively, according to the sequential
CD56
bright, CD56
dimNKG2A
+ and CD56
dimNKG2A
2 NK cell
subsets. Focussing on these two major clusters, we used DAVID
software (Table S2) to conduct a gene ontogeny analysis [20,21].
As Fig. 2B shows, the most representative group of genes in cluster
2 involved mRNA transcription regulation. It contained notably
GATA3, TCF7, VAV1 and SOX4, all described in T cells or NK
activation or differentiation pathways [25,26,27]. Moreover,
looking specifically at NK cell markers, we found substantial
downregulation of both CD117, a key marker of immature NK
cells, and of granzyme-K, a cytotoxic component of CD56
bright
NK cells, thereby confirming our flow cytometry results (Fig. 1)
(Table S2).
Conversely, cluster 4 was mainly characterised by the presence
of genes involved in signal transduction and cell structure,
including a number of tumour suppressor genes (FAT-2, DCC,
RASSF-4 and BRAF) that play a role in the control of cell
proliferation. In addition, expression increased for several genes in
this cluster that are involved in the regulation of NK cell functional
activities, such as KIRs (Kir2DL4, Kir3DL2, Kir2DS2, Kir2DL2
and Kir2DS1), granzyme-B and Ksp37 for cytotoxicity, and
CARD11 (CARMA1) for the regulation of cytokine/chemokine
production (Fig. 2B) (Table S2).
Although KIRs control the reactivity of mature NK cells, their
expression also influences the functional maturation of developing
NK cells. Fig. 3A shows that expression of whole KIRs, monitored
by a cocktail of KIR antibodies, linearly increases among
CD56
bright, CD56
dimNKG2A
+ and CD56
dimNKG2A
2 subsets.
More importantly, cell-surface expression of individual KIRs on
all three NK cell subsets revealed that inhibitory (KIR2DL1,
KIR2DL2, KIR2DL3, KIR3DL1, KIR2DL5) and activating
(KIR2DS1) receptors increased significantly (p,0.001, for each
marker) from the CD56
bright to CD56
dimNKG2A
+ subset and
from the CD56
dimNKG2A
+ to CD56
dimNKG2A
2 subset (Fig. 3B).
In contrast, KIR2DS4 rose only from the CD56
bright to CD56
dim
independently of NKG2A expression. These data were consistent
with the results obtained by gene array analysis (Fig. 2).
Together these results clearly show that specific combinations of
NKG2A and CD56 expression permit to differentiate three
phenotypicaly different subsets, including a CD56
dimNKG2A
+
subset displaying an intermediary profile between CD56
bright and
CD56
dimNKG2A
2 subsets.
NKG2A acquisition correlates with IFN-c production in
CD56
dimNKG2A
2 NK cells after IL12/IL18 stimulation
To determine the functional significance of these findings, we
assessed intracellular IFN-c production in highly purified
CD56
bright, CD56
dimNKG2A
+, and CD56
dimNKG2A
2 NK cell
subsets after IL12+IL18 stimulation (Fig. 4). A significantly higher
frequency of CD56
bright (compared with CD56
dim) NK cells
produced IFN-c, regardless of whether or not the latter expressed
NKG2A (p,0.001 in both cases). As Fig. 4A shows, around
80.966.2% of CD56
bright NK cells expressed IFN-c, whereas
only 49.7620.8% of CD56
dimNKG2A
+ and 33.8620.9%
CD56
dimNKG2A
2 NK cells did so. Moreover, the number of
IFN-c positive cells decreased significantly in the CD56
dim
Terminal NK Differentiation
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bright (Bright), CD56
dimNKG2A
+(D2A+) and CD56
dimNKG2A
2(D2A2) NK cell subsets from
healthy controls. Representative samples (left panels) and box and whiskers plots (right panels) are presented for each marker from at least 16
healthy controls. *: p,0.05; **: p,0.01; ***: p,0.001.
doi:10.1371/journal.pone.0011966.g001
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2 NK cells, compared with the CD56
dimNKG2A
+ subset
(p,0.05).
Next, we evaluated the effect of IL12+IL18 stimulation on the
CD56
dimNKG2A
2 NK subset and found that a fraction of these
cells re-expressed NKG2A (Fig. 4B). More intriguingly, up to 95%
of this de novo subpopulation expressed IFN-c, compared with
49.7620.8% of the CD56
dimNKG2A
2 subset (Fig. 4B). Similar
results were observed with CD94, but NKG2C, the activating
counterpart of NKG2A, did not increase after IL12+IL18 stimula-
tion (data not shown). In addition, CD56
bright and CD56
dim
NKG2A
+ cells still expressed NKG2A after IL12+IL18 stimula-
tion, regardless of their IFN-c production (Fig. 4B). These results
revealed that NKG2A could be specifically re-expressed on IFN-c-
producing-NKG2A
2 NK cells, after IL-12/IL-18 stimulation.
HLA-E expression on target cells restricts NK responsivity
to the CD56
dimNKG2A
2KIR
+ subset
Next we compared the degranulation capacity of these three
subsets by assessing their ability to express CD107a at the cell
surface. The response of CD56
bright NK cells to antibody-
dependent cell mediated cytotoxicity (ADCC) was poor, but
increased strongly in the CD56
dim subset, regardless of NKG2A
expression (Fig. 5A). When we checked the degranulation of these
NK cell subsets against HLA class-I negative K562 target cells, we
observed that the direct cytotoxic capacity of CD56
bright NK cells
was much lower than that of the CD56
dim subsets. More
importantly, the level of CD107 expression was higher in
CD56
dimNKG2A
+ than CD56
dimNKG2A
2 NK cells against
K562 target cells (Fig. 5A).
Because KIRs play an established role in the education of NK
cells, it was crucial to test their relative functional effects.
Accordingly, we assessed the degranulation capacity of the
following five NK cell subsets: CD56
bright, CD56
dimNKG2A
+
KIR
2, CD56
dimNKG2A
+KIR
+, CD56
dimNKG2A
2KIR
+ and
CD56
dimNKG2A
2KIR
2. As Fig. 5A and 5C show, CD56
dim
NKG2A
2KIR
2 NK cells had significantly lower degranulation
rates against K562 target cells than the other CD56
dim NK cell
subsets (p,0.001), explaining that CD56
dimNKG2A
2 cells,
regardless of KIR expression, are less able to degranulate against
HLA class-I negative targets. Nonetheless, CD56
dimNKG2A
2
Figure 3. Extensive analysis of KIR expression. Cell surface expression of whole KIRs (A), or single KIR (B) on CD56
bright (open bars),
CD56
dimNKG2A
+ (grey bars) and CD56
dimNKG2A
2 (black bars) NK cells subsets from 32 healthy controls. *: p,0,05; **: p,0.01; ***: p,0.001.
doi:10.1371/journal.pone.0011966.g003
Figure 2. Whole genome microarray analysis. CD56
brightCD16
2 (Bright), CD56
dimNKG2A
+ (D2A+) and CD56
dimNKG2A
2 (D2A2) NK cell subsets
from 4 healthy donors (#1, #2, #3 and #4) were sorted and analysed using pan-genomic microarrays. (A) Left panel, Hierarchical clustering analysis
of significantly modulated genes. The six clusters were numbered C1 to C6. Right Panel, alternative representation of each cluster showing the
relative intensity of genes expression. Median relative intensities are represented by a red line. (B) Gene ontogeny analysis was performed with DAVID
software on genes of clusters 2, 4 and 5. Highly significant terms are shown with the associated genes (boxes) and their expression profile in the three
NK cell subsets. Median relative intensities are represented by a red line.
doi:10.1371/journal.pone.0011966.g002
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2 NK cells retained a significant capacity to respond to
ADCC compared to the other CD56
dim subsets (Fig. 5A and 5C).
We next investigated whether degranulation of CD56
bright,
CD56
dimNKG2A
+KIR
2, and CD56
dimNKG2A
+KIR
+ NK cells
was significantly inhibited in the presence of HLA-E-transfected
721.221 target cells, compared with the same cells against non-
transfected 721.211 cells. Interestingly, CD56
dimNKG2A
2KIR
+
cells were more functional against 721.221 target cells expressing
HLA-E than against their non-transfected counterparts (Fig. 5B
and 5D), which suggest preferential expression of NKG2C on
CD56
dimNKG2A
2 cells. Taken together, functional data show
that each CD56
dim NK cell expressing at least one inhibitory
receptor is competent against HLA-I negative target cells.
However, only the CD56
dimNKG2A
2KIR
+ NK cells are
competent to kill HLA-E-expressing target cells.
Phenotypic changing correlate with stepwise decrease of
NKG2A and acquisition of KIR, suggesting a new complex
model of NK cells terminal differentiation
Showing that KIRs coupled to NKG2A highlight functional
subset specialization, we explored precisely the phenotype of these
subsets. We looked markers that might provide clues about NK
cell differentiation in the following five NK subsets: CD56
bright,
CD56
dimNKG2A
+KIR
2, CD56
dimNKG2A
+KIR
+ and CD56
dim
NKG2A
2KIR
+. Interestingly, the comparison of these subsets
Figure 4. IFN-c production is associated with NKG2A re-acquisition. (A) Intracellular expression of IFN-c by CD56
bright (Bright),
CD56
dimNKG2A
+ (D2A+) and CD56
dimNKG2A
2 (D2A2) NK cell subsets from 7 healthy donors, after cell sorting and IL-12/IL-18 overnight activation.
*: p,0.05; **: p,0.01; ***: p,0.001. (B) Representative example of NKG2A expression and IFN-c production, before (UT) and after stimulation with IL-
12/IL-18 in CD56
bright (Bright), CD56
dimNKG2A
+ (D2A+) and CD56
dimNKG2A
2 (D2A2) NK cell subsets.
doi:10.1371/journal.pone.0011966.g004
Figure 5. The CD56
dimNKG2A
2KIR
+ NK cells are the only one able to degranulate against HLA2E+ target cells. CD107a degranulation
assays of CD56
bright (Bright), CD56
dimNKG2A
+ (D2A+) and CD56
dimNKG2A
2 (D2A2) NK cell subsets were accessed without target, or against K562 or
RAJI cells in the presence of 1 mg of rituximab (ADCC) (A), or against 721.221 target cells that do or do not express HLA-E (LCL-221-AEH) (C). Box and
whiskers plots of CD107a degranulation capacities of CD56
bright (Bright), CD56
dimNKG2A
+KIR2 (D2A+KIR2), CD56
dimNKG2A
+KIR
+ (D2A+KIR+),
CD56
dimNKG2A
2KIR
+ (D2A2KIR+) and CD56
dimNKG2A
2KIR
2 (D2A2KIR2) NK cell subsets from 11 healthy controls. NK cells were tested without
target cells, against RAJI cells in the presence of 1 mg of rituximab (ADCC), or K562 cells (B) or 721.221 target cells that do or do not express HLA-E (D).
*: p,0.05; **: p,0.01; ***: p,0.001.
doi:10.1371/journal.pone.0011966.g005
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a significant decrease of CD62L, CD27 and granzyme-K levels
(Fig. 6A), with the progressive increase in markers associated with
maturation, including ILT-2, CD57, Siglec-9 and FCRL6
(Fig. 6B). Finally, we analyzed in more detail the specific features
of the hyporesponsive CD56
dimNKG2A
2KIR
2 NK cell subset.
Comparison between competent (NKG2A
2KIR
+) and hypore-
sponsive (NKG2A
2KIR
2) CD56
dim NK cells revealed that
hyporesponsive cells expressed significantly more CD62L, and
CD27 than competent cells. In contrast these hyporesponsive cells
Figure 6. Stepwise decrease of NKG2A and acquisition of KIRs is shown by specific markers of NK cell maturation. Expression of
CD62L, granzyme-K and CD27 (A) or ILT2, CD57, Siglec-9 and FCRL6 (B) on CD56
bright (Bright), CD56
dimNKG2A
+KIR
2 (D2A+KIR2), CD56
dimNKG2A
+KIR
+
(D2A+KIR+), CD56
dimNKG2A
2KIR
+ (D2A2KIR+) and CD56
dimNKG2A
2KIR
2 (D2A2KIR2) NK cell subsets from at least 16 healthy donors. *: p,0.05;
**: p,0.01; ***: p,0.001.
doi:10.1371/journal.pone.0011966.g006
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cells (Fig. 6B). Together, these data support a new complex model
of NK cell differentiation in which NKG2A expression, correlate
inversely with KIRs expression (Fig. 7).
Discussion
In this study, we set out to investigate the terminal differenti-
ation of NK cells, focussing on NKG2A and KIRs as key markers
during this dynamic process. Our data strongly endorse a new
model of NK cell differentiation that begins with CD56
bright cells,
all expressing high-density NKG2A
+ and few KIRs, and evolves to
a set of CD56
dimNKG2A
2KIR
+ cells, passing through interme-
diate stages, each characterised by unique phenotypic and
functional features. A part of our results agree with those in a
recent report presenting a simple linear differentiation model
based on the expression of CD94 [7]. However, differences in the
expression pattern of other NK receptors have been noticed when
comparing the inhibitory NKG2A
+ and the activating NKG2C
+
NK-cell subsets, which cannot be discriminated in CD94
+ cells
[28]. Furthermore, CD94 does not permit to conclude about
specific activities, because NKG2A and NKG2C have opposite
functions. The association reported between elevated numbers of
circulating NKG2C
+ NK cells and positive serology findings for
viruses suggests that these NKG2A and NKG2C receptors might
be involved in different stages of NK cell ontogenetic development
[29,30,31]. Therefore this dichotomy, impossible when using
CD94, is necessary for NK cells differentiation studies, particularly
following pathogens encountering.
It is well established that CD56
bright NK cells produce more
cytokines than CD56
dim NK cells in response to exogenous
cytokine stimulation [32,33]. We found that treatment with IL12/
IL18 increased the frequency of IFN-c production significantly
more in CD56
bright NK cells than in CD56
dimNKG2A
2 NK cells:
CD56
dimNKG2A
+ cells responded more vigorously in term of
IFN-c production than did CD56
dimNKG2A
2, but still signifi-
cantly far less than CD56
bright NK cells, consistent with the recent
data of Yu et al [7] on CD56
dimCD94
+ NK cells. Also, these results
were in line with previous reports showing that CD56
dimNK-
G2A
2KIR
+/2 NK cells have the developmental potential to
reacquire NKG2A after cytokines stimulation [34,35]. More
importantly, our data provide evidence that the partial recovery of
NKG2A correlates with IFN-c production in CD56
dimNKG2A
2
cells after IL-12/IL-18 stimulation. Interestingly, Gustafson et al
demonstrated that IFN-c induces, through STAT-1 pathway, a
high increase of HLA-E expression in exposed cells [36].
Therefore, IFN-c production might induce its own regulation
through HLA-E induction resulting in the inhibition of NKG2A
expressing cells. These findings also indicate that CD56
dim
NKG2A
2 phenotype does not represent an irreversible state for
NK cells; they also highlight the robust plasticity of NK cell
response to various stimuli.
Previous evidences support the hypothesis that NK cell
development proceeds sequentially from CD56
bright to CD56
dim
NK cells [5,6,7]. This model is buttressed by our data suggesting a
robust link between the acquisition of functional capacities and
both the stepwise decrease in NKG2A and the correlated
acquisition of KIRs. Notably, we compared the CD56
bright,
CD56
dimNKG2A
+KIR
2, CD56
dimNKG2A
+KIR
+, and CD56
dim
NKG2A
2KIR
+ subsets and observed a gradient in the expression
of NK markers between the three subsets, with a progressive
decrease in CD62L, CD27 and granzyme-K, all highly expressed
on CD56
bright cells from peripheral blood, together with a
progressive increase in receptors associated with maturity, such
as ILT-2, FCRL6, Siglec-9 and CD57. This notion of a continuum
or gradient along a specific pathway of differentiation is perfectly
illustrated by CD57 expression, which has been recognised as a
marker of in vitro replicative senescence of T lymphocytes [37] and
which is known to be absent on cord blood NK cells and
subsequently increase with elderly [12]. Similarly, Cooley et al
have shown that CD56
dimKIR
+ NK cells, which express high
levels of CD57, proliferate more slowly [34]. This supports our
model of NK cells terminal differentiation proposed in Fig. 7, in
which the NK cell repertoire gradually changes from a CD56
bright
toward a CD56
dim dominant response, whereby the CD56
dimNK-
G2A
+KIR
2 subset develops first into a CD56
dimNKG2A
+KIR
+
phenotype and then terminally differentiates into CD56
dimNK-
G2A
2KIR
+ cells. As show by our functional data, these three
CD56
dim subsets display the same ability to degranulate against
HLA-I
2 targets. More importantly, the acquisition of the terminal
differentiated CD56
dimNKG2A
2KIR
+ subset is crucial to acquire
the capacity to respond against HLA-E
+ target cells. Indeed, the
degranulation of this subset is even increased by HLA-E
expression on target cells. This particularity might be used in
order to fight viruses like HCMV, which increase HLA-E
expression on infected cells to escape immune system [38].
Figure 7. Model of terminal differentiation of NK cells. NK cell repertoire gradually changed from CD56
bright towards a CD56
dim dominant
response; CD56
dimNKG2A
+KIR
2 cells then develop into CD56
dimNKG2A
+KIR
+ and then terminally differentiate into CD56
dimNKG2A
2KIR
+ cells.
Expression of KIR in a few CD56
bright NK cells also suggested that a part of those cells give rise directly to CD56
dimNKG2A
+KIR
+. This model also
includes the potential re-expression of NKG2A on CD56
dimNKG2A
2 NK cells after stimulation. Hyporesponsive CD56
dimNKG2A
2KIR
2 NK cells are
integrated as cells that failed to acquire KIR before NKG2A loss due to their incompletely differentiate phenotype.
doi:10.1371/journal.pone.0011966.g007
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CD56
brightKIR
+ NK cells, which has previously been described
and which overlaps these developmental stages [39]. It has been
suggested that this KIR expression on CD56
bright subset reflects
their activation status in response to cytokines such as IL-15, which
is responsible for homeostatic proliferation [34]. We propose as an
alternative that a fraction of the CD56
dimNKG2A
+KIR
+ cells
might be directly derived from CD56
bright cells. Our results also
show that a substantial fraction of CD56
dim NK cells that lacked
both NKG2A and KIRs were hyporesponsive, even against the
HLA class I-deficient K562 target cells; however, the paucity of
available KIR mAb limited our study and prevents us from
concluding definitively that KIR
2 NK cells do not express any
KIR. Intriguingly, we observed that these CD56
dimNKG2A
2
KIR
2 hyporesponsive cells had partially preserved their capacity
for ADCC. This is consistent with their normal levels of perforin
and granzyme-B cytotoxic components, as initially described [40].
It is likely that other receptors expressed by NK cells contribute to
their education and may explain this activity. Recently Carrega
et al [41] showed that hyporesponsive NK cells are fully responsive
against autologous melanoma cells upon activation. In our study,
expression of CD62L, CD27, CD57, Siglec-9 and FCRL6,
suggests that CD56
dimNKG2A
2KIR
2 NK cells are not fully
differentiated, but can be re-educated under specific stimulation to
become fully functional, in line with our model (Fig. 7). This is
strong evidence that at least part of NK cell education might occur
in the periphery during immune response, as suggest by Juelke et al
[35].
Not surprisingly, multiple levels of tolerance keep fully
functional NK cells in check. It is now well established that
interaction between inhibitory receptors and their self-MHC class-
I ligands affects NK cell education. Different mechanisms to
maintain self-tolerance may accompany the different expression
and effector function profiles of the various NK cell subsets. The
mechanism underlying education of NK cells via inhibitory KIRs
and NKG2A receptors remains unknown, and the ontogenetic
development of tolerance is poorly understood. As shown in Fig. 7,
our model, which is based on phenotypic and functional
characteristics of the different NK cell subsets, neither refutes
nor supports any particular mechanism for the regulation of self-
tolerance, including licensing, arming, disarming or tuning/
rheostat [16,17,18].
Taken together, our data shed new light on NK cell physiology
and suggest a continuum of NK cell differentiation. The dynamics
of this process seems to be closely linked to KIR acquisition and
simultaneous NKG2A loss, and gives rise to NK cells responsive
against HLA-E
+ target cells. Our findings provide detailed insight
into the plasticity of the NK cell repertoire and allow our model to
include the failure of KIR acquisition before NKG2A loss in
hyporesponsive NK cells.
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